José Alcamí
Grup de recerca
- Sida i infecció per VIH Accredited researcher (R3A)
Publicacions destacades
-
Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals
Autors:Referència: Clinical Microbiology And Infection 2020. -
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.
Autors:Referència: Biochemical Pharmacology 2018. -
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection
Autors:Referència: Journal Of Infectious Diseases 2005. -
Absolute dependence on κB responsive elements for initiation and tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes
Autors:Referència: Embo Journal 1995.
Projectes destacats
-
TYROSINE KINASE INHIBITION: THE NEW FRONT IN HIV CURE EFFORTS.
Investigador/a principal: JOSÉ ALCAMI PERTEJOFinançador: Instituto de Salud Carlos III (Sede o evento)Codi: GRANT NUMBER: 1R01AI143567-01 / FAIN: R01AI143567Durada: 07/11/2018 - 31/10/2023 -
MECANISMOS DE RESTRICCIÓN A LA INFECCIÓN Y PROGRESIÓN DE LA INFECCIÓN POR EL VIH.
Finançador: Instituto de Salud Carlos III (Sede o evento)Durada: 01/01/2017 - 31/12/2019 -
RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)
Investigador/a principal: José Alcami PertejoFinançador: Instituto de Salud Carlos III (Sede o evento)Codi: RD16/0025/0012Durada: 01/01/2017 - 31/12/2021 -
EAVI 2020: EUROPEAN AIDS VACCINE INITIATIVE 2020
Investigador/a principal: José Alcami PertejoFinançador: Instituto de Salud Carlos III (Sede o evento); Unión EuropeaDurada: 01/11/2015 - 01/11/2020 -
AIM-AIV: HYDROXITIROSOL, A NEW GENERATION OF MICROBICIDES TARGETIN HIV THROUGH ANTIVIRAL AND ANTI-INFAMMATORY PATHWAYS
Investigador/a principal: José Alcami Pertejo, José Alcamí PertejoFinançador: Instituto de Salud Carlos III (Sede o evento); UECodi: U.E. 305938Durada: 01/12/2012 - 01/12/2014